These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16384843)

  • 1. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients.
    Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG
    Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
    Martins-Costa MC; Cunha LL; Lindsey SC; Camacho CP; Dotto RP; Furuzawa GK; Sousa MS; Kasamatsu TS; Kunii IS; Martins MM; Machado AL; Martins JR; Dias-da-Silva MR; Maciel RM
    Endocr Relat Cancer; 2016 Dec; 23(12):909-920. PubMed ID: 27807060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
    Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
    Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medullary thyroid carcinoma.
    Pacini F; Castagna MG; Cipri C; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.
    Chang JS; Chang CF; Yang WS; Chang TC
    Acta Cytol; 2011; 55(6):556-62. PubMed ID: 22156466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family.
    Qi XP; Ma JM; Du ZF; Ying RB; Fei J; Jin HY; Han JS; Wang JQ; Chen XL; Chen CY; Liu WT; Lu JJ; Zhang JG; Zhang XN
    PLoS One; 2011; 6(5):e20353. PubMed ID: 21655256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A.
    Bae SJ; Kim DJ; Kim JY; Park SY; Choi SH; Song YD; Ki CS; Chung JH
    Thyroid; 2006 Jun; 16(6):609-14. PubMed ID: 16839264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
    Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
    Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.